HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)

被引：0
|
作者：
Hasson, Hamid [1 ]
Galli, Laura [1 ]
Gallotta, Giulia [1 ]
Neri, Valentina [2 ]
Blanc, Pierluigi [3 ]
D'annunzio, Marco [4 ]
Morsica, Giulia [1 ]
Sollima, Salvatore [5 ]
Merli, Marco [1 ]
Lazzarin, Adriano [1 ,6 ]
Uberti-Foppa, Caterina [1 ]
机构：
[1] IRCCS Osped San Raffaele, Dept Infect Dis, I-20127 Milan, Italy
[2] L Spallanzani Natl Inst Infect Dis, Rome, Italy
[3] SS Annunziata Hosp, Dept Infect Dis, Florence, Italy
[4] Univ Bari, Inst Infect Dis, I-70121 Bari, Italy
[5] L Sacco Hosp Vialba, Dept Infect & Trop Dis, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
NEW MICROBIOLOGICA | 2012年 / 35卷 / 04期
关键词：
HAART-simplification strategy; Anti-HCV drugs; LPV/r monotherapy; Tolerability of HIV/HCV treatments; LOPINAVIR-RITONAVIR MONOTHERAPY; MAINTENANCE THERAPY; 2; NUCLEOSIDES; HIV; ANTIRETROVIRALS; SUPPRESSION; MANAGEMENT;
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naive to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
引用
收藏
页码：469 / 474
页数：6
相关论文
共 50 条
  • [1] HCV treatment in HIV/HCV co-infected patients A single center, observational study
    Androutsakos, T.
    Sipsas, N.
    Kontos, A.
    Hatzis, G.
    ARCHIVES OF HELLENIC MEDICINE, 2019, 36 (06): : 787 - 791
  • [2] The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients
    Sacchi, Alessandra
    Agrati, Chiara
    D'Offizi, Gianpiero
    Vlassi, Chrysoula
    Rozera, Gabriella
    Abbate, Isabella
    Capobianchi, Maria Rosaria
    Martini, Federico
    CLINICAL IMMUNOLOGY, 2011, 138 (02) : 178 - 186
  • [3] Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
    Li, Yuanyuan
    Li, Linghua
    Liu, Jun
    Zhang, Da-Wei
    Zhao, Fang
    Wang, Li
    Mahemure, Aizezi
    Xie, Ronghui
    Lei, Suyun
    Cai, Weiping
    Wang, Xicheng
    Shu, Zhanjun
    Chen, Xiejie
    Wang, Hui
    Wang, Fu-Sheng
    HEPATOLOGY INTERNATIONAL, 2018, 12 (05) : 465 - 473
  • [4] German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
    Beisel, Claudia
    Heuer, Martin
    Otto, Benjamin
    Jochum, Johannes
    Schmiedel, Stefan
    Hertling, Sandra
    Degen, Olaf
    Luth, Stefan
    van Lunzen, Jan
    zur Wiesch, Julian Schulze
    AIDS RESEARCH AND THERAPY, 2014, 11
  • [5] Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study
    Gonvers, Jean-Jacques
    Heim, Markus H.
    Cavassini, Matthias
    Muellhaupt, Beat
    Genne, Daniel
    Bernasconi, Enos
    Borovicka, Jan
    Cerny, Andreas
    Chave, Jean-Philippe
    Chuard, Christian
    Dufour, Jean-Francois
    Dutoit, Valerie
    Malinverni, Raffaelle
    Monnat, Martine
    Negro, Francesco
    Troilliet, Nicolas
    Oneta, Carl
    SWISS MEDICAL WEEKLY, 2010, 140
  • [6] A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study
    Cooper, Curtis
    la Porte, Charles
    Tossonian, Harout
    Sampalis, John
    Ackad, Nabil
    Conway, Brian
    HIV CLINICAL TRIALS, 2012, 13 (04): : 179 - 188
  • [7] Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil
    Sprinz, E.
    Bay, M. B.
    Lazzaretti, R. K.
    Jeffman, M. W.
    Mattevi, V. S.
    HIV MEDICINE, 2008, 9 (05) : 270 - 276
  • [8] Low Levels of Microbial Translocation Marker LBP Are Associated with Sustained Viral Response after Anti-HCV Treatment in HIV-1/HCV Co-Infected Patients
    Nystrom, Jessica
    Stenkvist, Jenny
    Haggblom, Amanda
    Weiland, Ola
    Nowak, Piotr
    PLOS ONE, 2015, 10 (03):
  • [9] Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
    Maughan, A.
    Sadigh, K.
    Angulo-Diaz, V.
    Mandimika, C.
    Villanueva, M.
    Lim, J. K.
    Ogbuagu, O.
    BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [10] The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART
    Jevtovic, Dj.
    Ranin, J.
    Salemovic, D.
    Pesic, I.
    Dragovic, G.
    Zerjav, S.
    Djurkovic-Djakovic, O.
    BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (01) : 21 - 25
12345